Pretreatment with d-myo-Inositol Trisphosphate Reduces Infarct Size in Rabbit Hearts: Role of Inositol Trisphosphate Receptors and Gap Junctions in Triggering Protection
- 1 September 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 314 (3) , 1386-1392
- https://doi.org/10.1124/jpet.105.087742
Abstract
Pretreatment with d-myo-inositol-1,4,5-trisphosphate hexasodium (d-myo-IP3), the sodium salt of the second messenger inositol 1,4,5-trisphosphate (IP3), is cardioprotective and triggers a reduction of infarct size comparable in magnitude to that obtained with ischemic preconditioning. However, this observation is enigmatic; whereas IP3 signaling is conventionally initiated by receptor binding, IP3 receptors are typically considered to be intracellular, and d-myo-IP3 is membrane-impermeable. We propose that this paradox is explained by the presence of poorly characterized external IP3 receptors and hypothesize that: 1) infarct size reduction with d-myo-IP3 is receptor-mediated; and 2) communication via gap junctions and/or hemichannels is required to initiate this protection. To investigate the role of receptor binding, isolated buffer-perfused rabbit hearts underwent 30 min of coronary occlusion (CO) and 2 h of reflow. Prior to CO, hearts received no treatment (controls), d-myo-IP3, l-myo-IP3 (enantiomer not recognized by the IP3 receptor), d-myo-IP3 + the IP3 receptor inhibitor xestospongin C (XeC), or XeC alone. Infarct size, assessed by tetrazolium staining, was reduced with d-myo-IP3 treatment, whereas hearts that received l-myo-IP3 or d-myo-IP3 + XeC showed no protection. To evaluate the contribution of gap junctions/hemichannels, additional control and d-myo-IP3-treated cohorts received a 5-min infusion of heptanol or Gap 27, two structurally distinct gap junction inhibitors, administered at doses confirmed to attenuate intercellular transmission of a gap junction-permeable fluorescent dye. There was no infarct-sparing effect of d-myo-IP3 in inhibitor-treated hearts. These data support the concepts that infarct size reduction with d-myo-IP3 is triggered by receptor binding and that communication via gap junctions/hemichannels is involved in initiating this protection.This publication has 40 references indexed in Scilit:
- Plasma and intracellular membrane inositol 1,4,5-trisphosphate receptors mediate the Ca2+ increase associated with the ATP-induced increase in ciliary beat frequencyAmerican Journal of Physiology-Cell Physiology, 2004
- Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin ICardiovascular Research, 2004
- Role of Leptin in the Development of Cardiac Hypertrophy in Experimental Animals and HumansCirculation, 2004
- Tyrphostin AG 126 inhibits development of postoperative ileus induced by surgical manipulation of murine colonAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Besides affecting intracellular calcium signaling, 2‐APB reversibly blocks gap junctional coupling in confluent monolayers, thereby allowing the measurement of single‐cell membrane currents in undissociated cellsThe FASEB Journal, 2003
- 2‐Aminoethoxydiphenyl borate (2‐APB) is a reliable blocker of store‐operated Ca2+entry but an inconsistent inhibitor of InsP3‐induced Ca2+releaseThe FASEB Journal, 2002
- Xestospongin C, a selective and membrane‐permeable inhibitor of IP3 receptor, attenuates the positive inotropic effect of α‐adrenergic stimulation in guinea‐pig papillary muscleBritish Journal of Pharmacology, 2000
- Peptides Homologous to Extracellular Loop Motifs of Connexin 43 Reversibly Abolish Rhythmic Contractile Activity in Rabbit ArteriesThe Journal of Physiology, 1997
- Inositol trisphosphate and calcium signallingNature, 1993
- IP 3 Receptor: Localization to Plasma Membrane of T Cells and Cocapping with the T Cell ReceptorScience, 1992